Prostate Carcinoma Cells That Have Resided in Bone Have an Upregulated IGF-I Axis

Prostate

Volumn 58, Issue 1, 2004, Pages 41-49

  Rubin, Janet ^a,d   Chung, L W K ^b   Fan, X ^a   Zhu, L ^a   Murphy, T C ^a   Nanes, M S ^a   Rosen, C J ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c JACKSON LABORATORY   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

C4 2B; IGFBP 2; LNCaP; RANKL; RUNX2

Indexed keywords

MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

AMINO ACID SEQUENCE; ARTICLE; BONE METASTASIS; CARCINOMA CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNORADIOMETRIC ASSAY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REAL TIME POLYMERASE CHAIN REACTION;

BONE NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; MEMBRANE GLYCOPROTEINS; PROSTATIC NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, RIBOSOMAL, 18S; UP-REGULATION;

EID: 0346725927     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10299     Document Type: Article

References (43)

1. Cook GB, Watson FR. Events in the natural history of prostate cancer: Using salvage curves, mean age distributions, and contingency coefficients. J Urol 1968;99(1):87-96.
2. Doherty A, Smith G, Banks L, Christmas T, Epstein RJ. Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: Implications for paracrine growth. J Pathol 1999;188(3):278-281.
3. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279(5350):563-566.
4. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76(9):1115-1118.
5. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998;90(12):911-915.
6. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: A meta-analysis. Br J Cancer 2001;85(7):991-996.
7. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL. Evidence that insulin-like growth factor 1 and growth hormone are required for prostate gland development. Endocrinology 1999;140(5):1984-1989.
8. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73(2):401-407.
9. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000;141(6):2257-2265.
10. Angelloz-Nicoud P, Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 1995;136(12):5485-5492.
11. Hong J, Zhang G, Dong F, Rechler MM. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 2002;277(12):10489-10497.
12. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61(16):6276-6280.
13. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000;60(20):5617-5620.
14. Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor 1: Action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22(3):243-252.
15. Damon SE, Maddison L, Ware JL, Plymate SR. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 1998;139(8):3456-3464.
16. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000;60(11):3058-3064.
17. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 1994;57(3):406-412.
18. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54(10):2577-2581.
19. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 2000;44(2):91-103 Jul 1;44(2).
20. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yung H, Zhau HE, Balian G, Chung LW. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metcastatic sublines. Int J Cancer 1998;77(6):887-894.
21. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morrs MD, Keller ET. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47(3):212-221.
22. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C, Chung LW. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002;277(4):2468-2476.
23. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107(10):1235-1244.
24. Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart S, Linkhart T, Mohan S, Baylink DS. Circulating and skeletal insulin-like growth factor-I(IGF-I) concentrations in two inbred strains of mice with different bone mineral densities. Bone 1997;21(3):217-223.
25. Rosen CJ, Churchill GA, Donahue LR, Shultz KL, Burgess JK, Powell DR, Ackert C, Beamer WG. Mapping quantitative trait loci for serum insulin-like growth factor-1 levels in mice. Bone 2000;27(4):521-528.
26. Rubin J, Ackert-Bicknell C, Zhu L, Fan X, Murphy T, Nanes M, Marcus R, Holloway L, Beamer W, Rosen C. Insulin like growth factor-I (IGF-I) regulates osteoprotegerin (OPG) and RANK ligand (RANKL) in vitro and osteoprotogerin in vivo. J Clin Endocrinol Metab 2002;87(9):4273-4279.
27. Chang SM, Chung LW. Interaction between prostatic fibroblast and epithelial cells in culture: Role of androgen. Endocrinology 1989;125(5):2719-2727.
28. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818.
29. Bouxsein ML, Rosen CJ, Turner CH, Ackert CL, Shultz KL, Donahue LR, Churchill G, Adamo ML, Powell DR, Turner RT, Muller R, Beamer WG. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. J Bone Miner Res 2002;17(4):570-579.
30. Rubin J, Murphy T, Fan X, Goldschmidt M, Taylor W. Mechanical strain inhibits RANKL expression through activation of ERK1/2 in bone marrow stromal cells. J Bone Miner Res 2002;17:1452-1460.
31. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000;278(2):175-184.
32. Menaa C, Reddy SV, Kurihara N, Maeda H, Anderson D, Cundy T, Cornish J, Singer FR, Bruder JM, Roodman GD. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 2000;105(12):1833-1838.
33. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delancy J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93(2):165-176.
34. Chen ME, Lin SH, Chung LW, Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 1998;273(28):17618-17625.
35. Taneja SS, Ha S, Garabedian MJ. Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression. J Cell Biochem 2001;84(1):188-199.
36. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001;7(9):2941-2948.
37. Khosla S, Hassoun AA, Baker BK, Liu F, Zein NN, Whyte MP, Reasner CA, Nippoldt TB, Tiegs RD, Hintz RL, Conover CA. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest 1998;101(10):2165-2173.
38. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95(7):3597-3602.
39. Kong YY. Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogodh ER, Van G, Nguyen LT, Ohashi PS, Laccy DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402(6759):304-309.
40. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993;53(5):1102-1106.
41. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23(6):824-854.
42. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 1999;140(8):3552-3561.
43. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002;20(3):833-841.